Phase 3 N=62 Comparision of Different Dose of Neostigmine at Advanced Decurarization
Anesthesia
Primary: Mesure of the Train-of-four (TOF) — 3.8; 4.5; 11.5; 19 minute
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=399 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 8.51; 7.29 Months — p=0.0199
Phase 3 N=46 Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Metastatic Cancer · Pain
Primary: Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II) — 39; 37 Participants
Phase 3 N=706 A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Melanoma
Primary: Progression-free Survival — 4.7; 4.9 months — p=0.51711
Phase 3 N=511 Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
Multidrug-resistant Tuberculosis
Primary: Time To Sputum Culture Conversion (SCC) During 6-Month Intensive Period Using The Mycobacteria Growth Indicator Tube (MGIT) System — 51; 57 Days — p=0.0562
Phase 3 N=50 Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
Multiple Sclerosis
Primary: Serum Level of TNF-α — 37.16; 28.79 Pg/ml
Phase 3 N=38 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels
Neonatal Abstinence Syndrome · Aromatherapy
Primary: Length of Hospitalization — 17.8; 11.4 days — p=0.03
Phase 3 N=69 Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Measuring the Safety and Efficacy of a New DMARD, Leflunomide Alone or in Combination With Traditional DMARD's. Participants Reaching ACR 20 Response. at 48 Weeks — 8…
Phase 3 N=1,647 Plaque Psoriasis Efficacy and Safety With Secukinumab
Plaque Psoriasis
Primary: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 — 552; 496 Participants — p=0.1499
Phase 3 N=23 A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 95.2; 9.5 percentage of participants
Phase 3 N=521 Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Plaque Psoriasis
Primary: Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12 — 142; 147 participants
Phase 3 N=17 Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
Obsessive-Compulsive Disorder · Generalized Anxiety Disorder
Primary: Psychometric Scores — 16.4; 18.86; 27.6; 24.3 units on a scale
Phase 3 N=31 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
Nephrotic Syndrome
Primary: Number of Participants Experienced a Relapse of Nephrotic Syndrome — 14; 15 Participants
Phase 3 N=5,022 A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Heart Failure · Coronary Artery Disease
Primary: Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke — 13.44; 14.27 Event rate per 100 patient-year — p=0.270
Phase 3 N=28 Carnitine Supplementation and Skeletal Muscle Function
Sarcopenia
Primary: Blood Inflammatory Marker — 2.6; 1.8; 2.9; 1.7 mg·L^-1